We are delighted that the OptiForm Solution Suite platform has won further industry recognition, having won the ‘Editor’s Choice’ category at the annual INTERPHEX awards earlier this year.
Somerset, N.J. and Barcelona, Spain (PRWEB) October 05, 2016
Catalent Pharma Solutions (Stand 3J16), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its OptiForm® Solution Suite and OptiForm® Solution Suite Bio platforms have won the ‘Excellence in Pharma: Contract Services and Outsourcing’ award at the annual CPhI Pharma Awards. The award was presented at a Gala Dinner on Oct. 4 at the world’s largest pharmaceutical meeting, CPhI Worldwide, which is currently taking place in Barcelona.
Catalent’s OptiForm Solution Suite is an integrated service designed for early stage small molecules, using a unique toolkit of formulation technologies and expertise. It incorporates comprehensive molecule characterization and parallel evaluation of four formulation technologies, including salt form optimization, lipid formulation, solid dispersion and particle size reduction. OptiForm Solution Suite matches the best formulation technologies to each molecule, and uses an accelerated parallel screening and development protocol, based on rigorous science and best-in-class scientific expertise, to provide in vivo study material in 12 weeks, including two weeks’ stability data.
To expand the service to the early phase development of peptides and macromolecules, OptiForm Solution Suite Bio was launched to rapidly screen biomolecules’ potential for non-invasive, oral delivery. It employs two proven formulation technologies, OptiGel™ Bio and Zydis® Bio, and uses a parallel screening model to deliver in vivo study material within three weeks.
“We are delighted that the OptiForm Solution Suite platform has won further industry recognition, having won the ‘Editor’s Choice’ category at the annual INTERPHEX awards earlier this year,” commented Julien Meissonnier, Catalent’s Vice President, Science & Technology. He added, “OptiForm Solution Suite offers easy, simple, fast and cost effective approaches for both small and macromolecules in early development phases. Our recent acquisition of Pharmatek will add their extensive early-phase drug development capabilities, and pharmaceutical spray dry expertise as a further option to overcome bioavailability issues.”
Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. The awards celebrate thinkers and creators breaking new ground and strongly advocates companies committed to driving the industry forward.
For further information or to arrange a meeting with a member of the executive team during the show, please contact Richard Kerns at NEPR (email@example.com).
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,200 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.
More products. Better treatments. Reliably supplied.™